Thrombolytic action of ticlopidine: Possible mechanisms

European Journal of Pharmacology

Volumn 308, Issue 1, 1996, Pages 61-67

  Gryglewski, Ryszard J ^a   Korbut, Ryszard ^a   Świȩs, Józef ^a   Kostka Tra̧bka, Elz̀bieta ^a   Bieroń, Krzysztof ^a   Robak, Jadwiga ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Anti platelet potency; Nitric oxide (NO); Prostacyclin; Thrombolysis; Ticlopidine; Tissue plasminogen activator

Indexed keywords

PROSTACYCLIN; TICLIDE; TICLOPIDINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ARTERY DISEASE; ARTICLE; BLOOD CLOT LYSIS; CAT; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 0030579851     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00256-7     Document Type: Article

References (42)

1. Albers, G.W., 1995, Antithrombotic agents in cerebral ischemia. Am. J. Cardiol. 75, 348.
2. Bertrand, M.E., H. Allain and J.M. Lablanche, 1990, Results of randomized trial of ticlopidine versus placebo for prevention of acute closure and restenosis after coronary angioplasty (PTCA). The TACT Study. XII Congress of the European Society of Cardiology, Abstract Suppl. P2022.
3. Blanchard, J.F., L.O. Carreras and M. Kindermans, 1994, Results of EMATAP, a double-blind, placebo controlled, multicenter trial of ticlopidine in patients with peripheral arterial disease, Nouv. Rev. Fr. Hematol. 35, 523.
4. Born, G.V.R., 1962, Aggregation of blood platelets by adenosine diphosphate and its reversal, Nature 194, 927.
5. Bruno, J.J., 1983, The mechanisms of action of ticlopidine, Thromb, Res. Suppl. 4, 59.
6. Corell, T., S.B. Pedersen, B. Lissau, E. Moilanen, T. Metsa-Ketela, H. Kankaanranta, P. Vuorinen, H. Vapaatalo, E. Rydel, R. Anderson, E. Marcinkiewicz, R. Korbut, R.J. Gryglewski, 1994, Pharmacology of mesoionic oxatriazole derivatives in blood, cardiovascular and respiratory systems, Pol. J. Pharmacol. 46, 553.
7. Defreyn, G., C. Gachet, P. Savi, F. Driot, J.P. Cazenave and J.P. Maffrand, 1991, Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits, Thromb. Haemost. 65, 186.
8. De Nucci, G., R.J. Gryglewski, T.D. Warner and J.R. Vane, 1988, Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc. Natl. Acad. Sci. USA 85, 2334.
9. Duniec, Z., J. Robak and R.J. Gryglewski, 1983, Antioxidant properties of some chemicals versus their influence on cyclooxygenase and lipoxygenase activities, Biochem. Pharmacol. 32, 2283.
10. Fujii, S., C.L. Lucore, W.E. Hopkins, J.J. Billadello and B.E. Sobel, 1989, Potential attenuation of fibrinolysis by growth factors released from platelets and their pharmacological implications, Am, J. Cardiol. 63, 1505.
11. Gachet, C., A. Stierle, J.P. Cazenave, P. Ohlmann, F. Lanza, C. Bouloux and J.P. Maffarand, 1990, The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb/IIIa complex in rat and in man, Biochem. Pharmacol. 40, 229.
12. Gent, M., 1993, A systematic overview of randomized trials of antiplatelet agents for the prevention of stroke, myocardial infarction, and vascular death, in: Ticlopidine, Platelets and Vascular Disease, eds. W.K. Hass and J.D. Easton (Springer Verlag, New York) p. 99.
13. Gent, M., J.D, Easton, V.C. Hachinski and the CATS Group, 1989, The Canadian American Ticlopidine study (CATS) in thromboembolic stroke, Lancet June 3, 1215.
14. Gorman, R.F., S. Bunting and O.V. Miller, 1977, Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 13. 377.
15. Grodzińska, L., E. Olszewski, E. Kostka-Tra̧bka, J. Turek, K. Bieroń, A. Goszcz, M. Sławiński and E. Reroń, 1993, Effective defibrotide therapy in patients with rapid progressive hearing loss, J. Drug Dev. 6, 15.
16. Gryglewski, R.J., 1995, Interactions between endothelial secretogogues, Ann. Med. 27, 427.
17. Gryglewski, R.J., R. Korbut, A. Ocetkiewicz and J. Stachura, 1978, In vivo method for quantitation of anti-platelet potency of drugs, Naunyn-Schmiedeberg's Arch. Pharmacol. 302, 25.
18. Gryglewski, R.J., R.M.J. Palmer and S. Moncada, 1986, Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor, Nature 320, 454.
19. Gryglewski, R.J., S. Chłopicki, J. Świȩs and P. Niezabitowski, 1995, Prostacyclin, nitric oxide and atherosclerosis, Ann. N.Y Acad. Sci. 748, 194.
20. Guillausseau, P.J., 1994, Preventive treatment of diabetic microangiopathy: blocking the pathogenic mechanism, Diabete Metab. 20, 219.
21. Harker, L.A. and J.J. Bruno, 1993, Ticlopidine's mechanism of action on human platelets, in: Ticlopidine, Platelets and Vascular Disease, eds. W.K. Hass and J.D. Easton (Springer Verlag, New York) p. 41.
22. Hayashi, J., S. Nakazawa and F. Oguma, 1994, Combined warfarin and antiplatelet therapy after St. Jude Medical valve replacement for mitral valve disease, J. Am. Cardiol. 23, 672.
23. Installe, E., M. Gozales and J.C. Schoevaerdts, 1981, Prevention by ticlopidine of platelet consumption during extracorporeal circulation for heart surgery and lack of effection operative and postoperative bleeding, J. Cardiovasc. Pharm. 3, 1174.
24. Keijer, J., M. Linders, A.J. Van Zonneveld. J. Ehrlich, J.P. De Boer and H. Pannekoek, 1991, The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance, Blood 78, 401.
25. Korbut, R., A. Ocetkiewicz, W. Da̧broś and R.J. Gryglewski, 1990, A biological method for studying the interaction between platelets and vascular endothelium. Thromb. Res. 57, 361.
26. Korbut, R., E. Marcinkiewicz, K. Cieślik and R.J. Gryglewski. 1995, The effect of nitric oxide donors on the release of plasminogen activator inhibitor (PAI) from rabbit platelets in vitro, J. Physiol. Pharmacol. 46, 37.
27. Lidbury, P.S., R. Korbut and J.R. Vane, 1990, Sodium nitroprusside modulates the fibrinolytic system in the rabbit, Br. J. Pharmacol. 101, 527.
28. Loosemore, T.M., T.C. Chalmers and J.A. Dormandy, 1994, A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease, Int. Angiol. 13, 133.
29. Maffrand, J.P., G. Defreyn, A. Bernat, D. Delebassée and A.M. Tissinier, 1988, Reviewed pharmacology of ticlopidine, Angiologie 77 (suppl.), 6.
30. Milutinovic. S., V. Gasparovic and E. Milutinovic, 1993, Ticlopidine improves dialysis clearance of solutes in uremic patients by reducing blood clotting in dialysis fibers. Int. J. Artif. Organs 16, 249.
31. Mills, D.C., R. Puri, C.J. Hu, C. Minniti, G. Grana, M.D. Freedman and R.F. Colman, 1992, Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler. Thromb. 12, 430.
32. Moncada, S., R.J. Gryglewski, S. Bunting and J.R. Vane, 1976, A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (Prostaglandin X) which prevents platelet aggregation, Prostaglandins 12, 715.
33. Moore, P.K., 1. Hussani and R. Bhardwaj, 1988, Prostanoids stimulate fibrinolysis in the rat. Arch. Int. Pharmacodyn. 296, 155
34. Robak, J. and R.J. Gryglewski, 1993, Nitric oxide donors as generators and scavengers of superoxide anions, Pol. J. Pharmacol. 45, 51.
35. 3H]-2-methylthio ADP to rat platelets - effect of clopidogrel and ticlopidine, J. Pharmacol. Exp. Ther. 269, 772.
36. Szczeklik, A., M. Kopeć, K. Sładek, J. Musiał, J. Chmielewska, E. Teisseyere, G. Dudek-Wojciechowska and M. Palester-Chlebowczyk. 1983, Prostacyclin and the fibrinolytic system in ischemic vascular disease, Thromb, Res. 29, 655.
37. Teitelbaum, P., 1993, Pharmacodynamics and pharmacokinetics of ticlopidine, in: Ticlopidine, Platelets and Vascular Disease, eds. W.K. Hass and J.D. Easton (Springer Verlag, New York) p. 27.
38. TIMAD Study Group, 1990, Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy, Arch. Ophthal. 108, 1577.
39. Verstraete, M., 1994, Primary and secondary prevention of arterial thromboembolism, Br. Med. Bull. 50, 946.
40. Von Kaulla, K.N. and R.L. Schultz, 1958, Methods for evaluation of human fibrinolysis. Am. J. Clin. Pathol. 29, 104.
41. Wu, K.K. and J.C. Hoak, 1974, A new method for the quantitative detection of platelet aggregates in patients with arterial insufficiency, Lancet ii, 924.
42. Yao, S.K., J.C. Ober, J.J. Ferguson, J.P. Maffrand, H.V. Anderson, L.M. Buja and J.T. Willerson, 1994, Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis, Am. J. Physiol. 267, H488.